* 34 



Page 2 - The Honorable Gerry Studds 



The National Institute of Allergy and Infectious Diseases (NIAID) AIDS Clinical Drug 

 Development Committee considered the Genelabs formulation of trichosanthin, known as 

 GLQ223, in February 1992. Based on available scientific data, they recommended that 

 further clinical evaluation of GLQ223 not be supported by NIAID at that time. 



I hope this answers your questions. Should you require further information please do not 

 hesitate to call me at (301) 496-8721. 



Sincerely, 



Michael,^. Grever, M.D. 



Associate Director 



Developmental Therapeutics Program 



